Wiedemann–Steiner Syndrome with a Pathogenic Variant in KMT2A from Taiwan

Chung-Lin Lee, Chih-Kuang Chuang, Huei-Ching Chiu, Ru-Yi Tu, Yun-Ting Lo, Ya-Hui Chang, Hsiang-Yu Lin, and Shuan-Pei Lin

Abstract: Wiedemann–Steiner syndrome (WSS) is a rare genetic disorder. Patients with WSS have characteristics of growth retardation, facial dysmorphism, hypertrichosis cubiti (HC), and neurodevelopmental delays. WSS is in an autosomal dominant inherited pattern caused by a mutation of the KMT2A gene (NM_001197104.2). In this article, we discuss a 5-year-old boy who has mild intellectual disability (ID), hypotonia, HC, hypertrichosis on the back, dysmorphic facies, psychomotor retardation, and growth delay. Trio-based whole-exome sequencing (trio-WES) was carried out on this patient and his parents, confirming the variants with Sanger sequencing. Trio-WES showed a de novo mutation of the KMT2A gene (NM_001197104.2: c.4696G>A, p.Gly1566Arg). On the basis of the clinical features and the results of the WES, WSS was diagnosed. Therefore, medical professionals should consider a diagnosis of WSS if patients have growth retardation and development delay as well as hirsutism, particularly HC.

Keywords: KMT2A; Wiedemann–Steiner syndrome; whole-exome sequencing; Taiwan
have been reported in the Leiden Open Variation Database (https://databases.lovd.nl/shared/genes/KMT2A) accessed on 5 July 2021 [3,6–14]. In the Human Gene Mutation Database (HGMD) (http://www.hgmd.cf.ac.uk/ac/gene.php?gene=KMT2A) accessed on 5 July 2021, 163 variants have been documented. More patients have been diagnosed with WSS using whole-exome sequencing (WES).

Until now, the complete WSS phenotype has not been fully understood. In this article, we discuss a 5-year-old Taiwanese boy with the clinical features of WSS using trio-based WES (trio-WES) to identify a de novo missense pathogenic variation of the KMT2A gene.

2. Case Report

This patient was born at 38 weeks’ gestation in a normal, spontaneous delivery, with a birthweight of 3225 g (29th percentile, \(Z\) score = −0.55), a body length of 48 cm (23rd percentile, \(Z\) score = −0.75), and a head circumference of 35 cm (34th percentile, \(Z\) score = −0.42). The patient’s parents were non-consanguineous, and they were phenotypically normal. The boy was referred to our genetic clinic due to mild ID and growth delay. At our clinic, the patient’s weight, and height were 16.6 kg (20th percentile, \(Z\) score = −0.83), 104.9 cm (19th percentile, \(Z\) score = −0.82), respectively. Physical examination showed dysmorphic facies and thick hair (Figure 1a,b); hypertrichosis on the back, arms, and lower limbs but not on the abdomen; and HC. The dysmorphic facies included a mildly coarse face with mild mid-face hypoplasia, mild trigonocephaly, an always-open mouth with a mild tongue protrusion, and hypertelorism. He had no feeding problems, vertebral block, sacral dimple, and renal or cardiac malformations. No other family members have similar symptoms.

We collected peripheral blood from the patient and his parents for genomic DNA at the age of 5 years. Trio-WES was carried out by the National Health Research Institutes (Taipei, Taiwan). They used the Illumina HiSeq Xten system. The trimmed reads were mapped to the reference human genome (hg19). We identified the variants using the following databases: the Single Nucleotide Polymorphism Database (https://www.ncbi.nlm.nih.gov/snp/) accessed on 5 July 2021, ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) accessed on 5 July 2021, the Genome Aggregation Database (http://gnomad.broadinstitute.org/) accessed on 5 July 2021, the Exome Aggregation Consortium (http://exac.broadinstitute.org/) accessed on 5 July 2021, the 1000 Genomes Project (http://browser.1000genomes.org/)

2. Case Report

This patient was born at 38 weeks’ gestation in a normal, spontaneous delivery, with a birthweight of 3225 g (29th percentile, \(Z\) score = −0.55), a body length of 48 cm (23rd percentile, \(Z\) score = −0.75), and a head circumference of 35 cm (34th percentile, \(Z\) score = −0.42). The patient’s parents were non-consanguineous, and they were phenotypically normal. The boy was referred to our genetic clinic due to mild ID and growth delay. At our clinic, the patient’s weight, and height were 16.6 kg (20th percentile, \(Z\) score = −0.83), 104.9 cm (19th percentile, \(Z\) score = −0.82), respectively. Physical examination showed dysmorphic facies and thick hair (Figure 1a,b); hypertrichosis on the back, arms, and lower limbs but not on the abdomen; and HC. The dysmorphic facies included a mildly coarse face with mild mid-face hypoplasia, mild trigonocephaly, an always-open mouth with a mild tongue protrusion, and hypertelorism. He had no feeding problems, vertebral block, sacral dimple, and renal or cardiac malformations. No other family members have similar symptoms.

![Figure 1](image1.png)

Figure 1. Physical appearance of a 5-year-old boy with WSS. Dysmorphic facies (a), depressed nasal bridge (b) and thick hair (a,b). Dysmorphic facies, such as mildly coarse face with mild mid-face hypoplasia, mild trigonocephaly, an always-open mouth with a mild tongue protrusion, and hypertelorism (a).

We collected peripheral blood from the patient and his parents for genomic DNA at the age of 5 years. Trio-WES was carried out by the National Health Research Institutes (Taipei, Taiwan). They used the Illumina HiSeq Xten system. The trimmed reads were mapped to the reference human genome (hg19). We identified the variants using the following databases: the Single Nucleotide Polymorphism Database (https://www.ncbi.nlm.nih.gov/snp/) accessed on 5 July 2021, ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/) accessed on 5 July 2021, the Genome Aggregation Database (http://gnomad.broadinstitute.org/) accessed on 5 July 2021, the Exome Aggregation Consortium (http://exac.broadinstitute.org/) accessed on 5 July 2021, the 1000 Genomes Project (http://browser.1000genomes.org/)
accessed on 5 July 2021, and HGMD (http://www.hgmd.cf.ac.uk/) accessed on 5 July 2021. We confirmed the identified variants via Sanger sequencing and interpreted the variants using the guidelines of the American College of Medical Genetics and Genomics (ACMG) [15].

We identified a missense variant with heterozygous state in the KMT2A gene (NM_001197104.2: c.4696G>A, p.Gly1566Arg), which we confirmed via Sanger sequencing (Figure 2a,b). The patient’s parents did not have this variant and it indicated a de novo variant. This variant was reported in ClinVar and was classified as a likely pathogenic (ACMG criteria code: PS2+PP2+PP4).

Figure 2. NM_001197104.2: c.4696G>A (p.Gly1566Arg) variation by Sanger sequencing. (a) Patient family tree. The blank squares and circle indicate unaffected males and females, respectively; the filled square indicates an affected male, and the arrow indicates the proband. (b) Electrophogram of heterozygous KMT2A c.4696G>A (red arrow). Both parents carried the wild-type sequence at this nucleotide.

3. Discussion

Wiedemann et al. and Steiner and Marques reported and defined WSS in 1989 and 2000, respectively [1,2]. Koenig et al. reported three additional cases in 2010 [16]. Different clinical phenotypes exist according to ethnicity. For example, in a French cohort, 65%, 61%, and 33% of 33 cases had eating difficulties, HC, and microcephaly, respectively [3]. In addition, eating difficulties, HC, and microcephaly were noted in 31%, 44%, and 50% of 16 cases, respectively, in a Chinese cohort [12]. HC is seen in most patients. However, there are reports of patients who do not have HC in the literature [3,4,13,17,18]. Neurodevelopmental disorders, including WSS, are related to variations of the KMT2A gene [7]. Molecular diagnoses such as WES, whole-genome sequencing, and targeted sequencing for the KMT2A gene could be useful for genetic counseling and patient care. Additional WSS cases could be found using WES, especially trio-WES [3,12,19,20].

The major variants of the previously described WSS cases were de novo null variants [3,8,12,13,20]. KMT2A gene missense variants made up a small but significant portion [3,7,12]. The ClinVar database (2021/02/09) reported 113 variants of the KMT2A gene associated with WSS. Among these variants, 67 are classified as pathogenic, 22 as likely pathogenic, 23 as of uncertain significance, 1 as likely benign, and none as benign. Furthermore, 32 are identified as frameshift small indels, 44 as missense mutations, 26 as nonsense mutations, 9 as splicing mutations, and 2 as antisense RNA. Because the exons 3 and exon 27 are much larger than the other exons, about 60% of the mutations are located in these regions.
According to a previous study with a cohort of 33 French WSS cases [3], frameshift (41%), nonsense (28%), and missense (28%) were the most frequent types of mutation. In another study with a Chinese cohort of 16 patients [12], the results of the mutation spectrum were like those of the French cohort. In our study, we present a 5-year-old Taiwanese boy with a de novo missense variant of KMT2A (NM_001197104.2: c.4696G>A, p.Gly1566Arg). His symptoms, which are compatible with WSS, include mild ID; growth delay; dysmorphic facies and thick hair; and hypertrichosis on the back, arms, and lower limbs but not on the abdomen.

HMT is encoded by the KMT2A gene. It is an important gene expression regulator in early development. HMT regulates multiple Wnt-related and Hox-related genes in histone H3 lysine 4 methylation [21]. Due to the function of HMT, the phenotypes of patients with WSS are complex. The phenotypes involve multiple systems, such as organic problems, developmental delay, ID [3,16], distinct craniofacial features, and skeletal anomalies [22].

Patients with language delay and ID require special education classes with regular speech and occupational therapies. If symptoms of hypotonia are noted, patients should have carnitine supplementation (in our patient, 2018/11/19: Plasma Free Carnitine: 40.9 µmol/L, normal range: 30~45.4 µmol/L; Plasma Total Carnitine: 49.9 µmol/L, normal range: 36.6~54 µmol/L). For patients with cardiac anomalies, surgical treatment should be considered. Because of growth retardation, children with WSS should have their pituitary function investigated. If biochemical evidence of growth hormone deficiency is noted, a pituitary magnetic resonance imaging scan should be considered, and patients should receive recombinant human growth hormone treatment. All these treatments can help patients with WSS survive with a better quality of life. Table 1 shows the recommended multi-disciplinary plan of care for individuals with WSS.

Table 1. Recommended multi-disciplinary plan of care for Wiedemann-Steiner Syndrome.

| Subspecialist | Considerations/Screening | Evaluation |
|---------------|--------------------------|------------|
| Development   | Language delay and intellectual disability | Regular speech and occupational therapies |
| Neurology     | Hypotonia                | Carnitine supplementation |
| Endocrinology | Growth retardation        | Pituitary magnetic resonance imaging scan and recombinant human growth hormone treatment |
| Cardiology    | Cardiac anomalies         | Surgical treatment |
| Geneticist    | KMT2A gene analysis and genetic counseling | Diagnostic discussion and family planning |

WES, a powerful tool used to identify disease-causing variants, allows the relationship between genotype and phenotype to become clearer. Shashi et al. [23] stated that next-generation sequencing should be applied if a diagnosis has not been confirmed after using more traditional approaches. Patients with genetic disorders, who often experience considerable psychosocial and economic burdens, can benefit from WES due to the increased rate of genetic disorders and cost savings. WSS prevalence would be updated if more patients were diagnosed using WES.

4. Conclusions

In summary, we discussed a 5-year-old Taiwanese boy who was diagnosed with WSS via clinical features and trio-WES. He is the first patient with WSS presented in Taiwan. WSS is a rare genetic disorder that combines with sporadic syndrome and phenotypic heterogeneity. Therefore, our findings can be valuable in genetic diagnosis and mutation-based screening.

Author Contributions: C.-L.L. drafted the manuscript. S.-P.L. and H.-Y.L. participated in the patient’s follow-up and helped draft the manuscript. C.-K.C., R.-Y.T. and Y.-T.L. performed the biochemical analyses and revised the manuscript. H.-C.C. and Y.-H.C. were responsible for patient screening and revised the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.
**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Mackay Memorial Hospital’s Institutional Review Board of MMH-E-110-16 in 5 March 2021.

**Informed Consent Statement:** Written informed consent has been obtained from the patient(s) to publish this paper.

**Acknowledgments:** We acknowledge the participation of the study patients and their families. This study was supported by research grants from the Ministry of Science and Technology, Executive Yuan, Taiwan (MOST-110-2314-B-195-010-MY3, MOST-110-2314-B-195-014, MOST-110-2314-B-195-029, MOST-109-2314-B-195-024, MOST-108-2314-B-195-012, and MOST-108-2314-B-195-014) and from MacKay Memorial Hospital (MMH-E-110-16, MMH-E-109-16, MMH-E-108-16, MMH-MM-10801, and MMH-107-82).

**Conflicts of Interest:** The authors declare that they have no conflicts of interest.

**References**

1. Wiedemann, H.R.; Kunze, J.; Dibbern, H. *Atlas of Clinical Syndromes*, 2nd ed.; Wolfe Publishing Ltd.: London, UK, 1989; pp. 198–199.

2. Steiner, C.E.; Marques, A.P. Growth deficiency, mental retardation and unusual facies. *Clin. Dysmorphol.* 2000, 9, 155–156. [CrossRef] [PubMed]

3. Baer, S.; Afenjar, A.; Smol, T.; Piton, A.; Gérard, B.; Alembik, Y.; Bienvenu, T.; Boursier, G.; Boute, O.; Colson, C.; et al. Wiedemann-Steiner syndrome as a major cause of syndromic intellectual disability: A study of 33 French cases. *Clin. Genet.* 2018, 94, 141–152. [CrossRef] [PubMed]

4. Jones, W.D.; Dafou, D.; McEntagart, M.; Woollard, W.J.; Elmslie, F.V.; Holder-Espinasse, M.; Irving, M.; Saggar, A.K.; Smithson, S.; Trembath, R.C.; et al. De novo mutations in MLL cause Wiedemann-Steiner syndrome. *Am. J. Hum. Genet.* 2012, 91, 358–364. [CrossRef] [PubMed]

5. Ansari, K.I.; Mishra, B.P.; Mandal, S.S. MLL histone methylases in gene expression, hormone signaling and cell cycle. *Front. Biosci.* 2009, 14, 3483–3495. [CrossRef] [PubMed]

6. Arora, V.; Puri, R.D.; Bijarnia-Mahay, S.; Verma, I.C. Expanding the phenotypic and genotypic spectrum of Wiedemann-Steiner syndrome: First patient from India. *Am. J. Med. Genet. Part A* 2020, 182, 953–956. [CrossRef] [PubMed]

7. Chan, A.J.S.; Cytrynbaum, C.; Hoang, N.; Ambrozewicz, P.M.; Weksberg, R.; Drnec, I.; Ritzema, A.; Schachar, R.; Walker, S.; Uddin, M.; et al. Expanding the neurodevelopmental phenotypes of individuals with de novo KMT2A variants. *NPJ Genom. Med.* 2019, 4, 9. [CrossRef] [PubMed]

8. Chen, M.; Liu, R.; Wu, C.; Li, X.; Wang, Y. A novel de novo mutation (p.Pro1310Glnfs*46) in KMT2A caused Wiedemann-Steiner syndrome in a Chinese boy with postnatal growth retardation: A case report. *Mol. Biol. Rep.* 2019, 46, 5555–5559. [CrossRef] [PubMed]

9. Feldman, H.R.; Dlouhy, S.R.; Lah, M.D.; Payne, K.K.; Weaver, D.D. The progression of Wiedemann-Steiner syndrome in adulthood and two novel variants in the KMT2A gene. *Am. J. Med. Genet. Part A* 2019, 179, 300–305. [CrossRef] [PubMed]

10. Grangeia, A.; Leao, M.; Moura, C.P. Wiedemann-Steiner syndrome in two patients from Portugal. *Am. J. Med. Genet. Part A* 2020, 182, 25–28. [CrossRef] [PubMed]

11. Jinxiu, L.; Shuimei, L.; Ming, X.; Jonathan, L.C.S.; Xiangju, L.; Wenyuan, D. Wiedemann-Steiner syndrome with a de novo mutation in KMT2A: A case report. *Medicine* 2020, 99, e19813. [CrossRef] [PubMed]

12. Li, N.; Wang, Y.; Yang, Y.; Wang, P.; Huang, H.; Xiong, S.; Sun, L.; Cheng, M.; Song, C.; Cheng, X.; et al. Description of the molecular and phenotypic spectrum of Wiedemann-Steiner syndrome in Chinese patients. *Orphanet J. Rare Dis.* 2018, 13, 178. [CrossRef] [PubMed]

13. Ramirez-Montano, D.; Pachajoa, H. Wiedemann-Steiner syndrome with a novel pathogenic variant in KMT2A: A case report. *Colomb. Med.* 2019, 50, 40–45. [CrossRef] [PubMed]

14. Styole, G.; Banka, S.; Langley, C.; Jones, E.A.; Banerjee, I. Growth hormone deficiency as a cause for short stature in Wiedemann-Steiner Syndrome. *Endocrinol. Diabetes Metab. Case Rep.* 2018, 18, 85. [CrossRef] [PubMed]

15. Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Hegde, M.; Lyon, E.; Spector, E.; et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet. Med.* 2015, 17, 405–424. [CrossRef]

16. Koenig, R.; Meinecke, P.; Kuechler, A.; Schäfer, D.; Müller, D. Wiedemann-Steiner syndrome: Three further cases. *Am. J. Med. Genet. Part A* 2018, 99, 1902–1904. [CrossRef] [PubMed]

17. Aggarwal, A.; Rodriguez-Buritica, D.F.; Northrup, H. Wiedemann-Steiner syndrome: Novel pathogenic variant and review of literature. *Eur. J. Med. Genet.* 2017, 60, 285–288. [CrossRef]

18. Demir, S.; Gürkan, H.; Öz, V.; Yalçıntepe, S.; Atlı, E.I.; Atlı, E. Wiedemann-Steiner Syndrome as a Differential Diagnosis of Cornelia de Lange Syndrome Using Targeted Next-Generation Sequencing: A Case Report. *Mol. Syndromol.* 2021, 12, 46–51.
19. Strom, S.P.; Lozano, R.; Lee, H.; Dorrani, N.; Mann, J.; O’Lague, P.F.; Mans, N.; Deignan, J.L.; Vilain, E.; Nelson, S.F.; et al. De novo variants in the KMT2A (MLL) gene causing atypical Wiedemann-Steiner syndrome in two unrelated individuals identified by clinical exome sequencing. *BMC Med. Genet.* **2014**, *15*, 49. [CrossRef]

20. Wang, X.; Zhang, G.; Lu, Y.; Luo, X.; Wu, W. Trio-WES reveals a novel de novo missense mutation of KMT2A in a Chinese patient with Wiedemann-Steiner syndrome: A case report. *Mol. Genet. Genom. Med.* **2021**, *9*, e1533. [CrossRef]

21. Milne, T.A.; Briggs, S.D.; Brock, H.W.; Martin, M.E.; Gibbs, D.; Allis, C.D.; Hess, J.L. MLL targets SET domain methyltransferase activity to Hox gene promoters. *Mol. Cell* **2002**, *10*, 1107–1117. [CrossRef]

22. Enokizono, T.; Ohto, T.; Tanaka, R.; Tanaka, M.; Suzuki, H.; Sakai, A.; Imagawa, K.; Fukushima, H.; Iwabuti, A.; Fukushima, T.; et al. Preaxial polydactyly in an individual with Wiedemann-Steiner syndrome caused by a novel nonsense mutation in KMT2A. *Am. J. Med. Genet. Part A* **2017**, *173*, 2821–2825. [CrossRef] [PubMed]

23. Shashi, V.; McConkie-Rosell, A.; Rosell, B.; Schoch, K.; Vellore, K.; McDonald, M.; Jiang, Y.H.; Xie, P.; Need, A.; Goldstein, D.B. The utility of the traditional medical genetics diagnostic evaluation in the context of next-generation sequencing for undiagnosed genetic disorders. *Genet. Med.* **2014**, *16*, 176–182. [CrossRef] [PubMed]